Dishman Carbogen Amcis Ltd

Dishman Carbogen Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dishman Carbogen Amcis Ltd

₹ 280 0.27%
13 Dec - close price
dishmangroup.com BSE: 540701 NSE: DCAL
About

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Key Points

Business Segments & Revenue Contribution

Website BSE NSE
  • Market Cap ₹ 4,384 Cr.
  • Current Price ₹ 280
  • High / Low ₹ 308 / 133
  • Stock P/E
  • Book Value ₹ 366
  • Dividend Yield 0.00 %
  • ROCE 0.02 %
  • ROE -2.64 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.76 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 4.91% over past five years.
  • Company has a low return on equity of -0.65% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE SmallCap Nifty Microcap 250 BSE Healthcare BSE Allcap Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
459 562 569 541 614 640 619 723 587 651 655 524 789
360 453 547 452 535 526 567 602 526 610 592 495 642
Operating Profit 99 110 22 88 79 114 51 122 61 41 63 29 147
OPM % 22% 19% 4% 16% 13% 18% 8% 17% 10% 6% 10% 6% 19%
7 19 -8 6 9 4 -39 7 5 6 4 -4 4
Interest 14 15 16 19 20 22 24 28 27 33 31 32 37
Depreciation 74 75 84 75 80 50 76 70 75 80 85 71 72
Profit before tax 19 38 -85 -0 -12 46 -88 29 -36 -66 -49 -78 42
Tax % 40% 8% -48% -1,437% -18% -3% -19% 42% 13% -10% 42% 0% 21%
11 35 -45 4 -10 47 -71 17 -41 -60 -70 -78 33
EPS in Rs 0.71 2.26 -2.85 0.26 -0.64 3.00 -4.51 1.08 -2.61 -3.80 -4.46 -4.95 2.11
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
1,031 1,714 1,695 2,059 2,044 1,912 2,141 2,413 2,616 2,619
830 1,261 1,249 1,507 1,540 1,638 1,809 2,081 2,329 2,339
Operating Profit 201 452 445 552 503 274 331 332 286 280
OPM % 20% 26% 26% 27% 25% 14% 15% 14% 11% 11%
14 26 46 54 39 16 29 -20 22 10
Interest 56 49 49 57 62 48 57 86 120 133
Depreciation 69 214 211 240 283 308 308 281 311 308
Profit before tax 91 216 231 309 197 -65 -4 -55 -122 -151
Tax % 12% 33% 33% 32% 20% 154% -524% -45% 26%
80 145 155 210 159 -165 18 -30 -153 -174
EPS in Rs 9.58 13.03 10.10 -10.53 1.15 -1.90 -9.79 -11.10
Dividend Payout % 0% 0% 0% 2% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 5%
3 Years: 11%
TTM: 2%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 4%
TTM: -7183%
Stock Price CAGR
10 Years: %
5 Years: 18%
3 Years: 9%
1 Year: 74%
Return on Equity
10 Years: %
5 Years: 0%
3 Years: -1%
Last Year: -3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 16 0.00 32 32 31 31 31 31 31 31
Reserves 863 4,814 5,075 5,347 5,684 5,667 5,518 5,778 5,596 5,705
868 950 1,095 1,042 1,357 1,589 1,830 2,209 2,313 2,507
334 811 967 899 1,121 1,068 1,255 1,421 1,631 1,937
Total Liabilities 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,571 10,180
1,012 4,852 5,066 5,098 5,678 5,698 5,773 6,188 6,724 7,159
CWIP 307 133 151 175 234 486 780 1,043 646 580
Investments 1 40 196 167 191 172 324 249 102 104
761 1,550 1,757 1,881 2,091 2,000 1,758 1,959 2,098 2,338
Total Assets 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,571 10,180

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
203 303 226 282 585 513 355 266 384
-231 -107 -297 -169 -442 -380 -619 -494 -230
25 -137 78 -102 -98 -11 130 250 -22
Net Cash Flow -3 59 7 11 46 122 -133 22 132

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 60 61 96 79 103 80 81 89 64
Inventory Days 272 473 525 496 462 402 526 568 540
Days Payable 172 95 201 176 226 132 158 155 149
Cash Conversion Cycle 160 439 419 399 340 350 449 502 455
Working Capital Days 49 117 129 135 124 135 115 90 100
ROCE % 5% 6% 4% 0% 1% 1% 0%

Shareholding Pattern

Numbers in percentages

4 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
4.60% 5.50% 5.85% 6.20% 7.20% 9.34% 8.90% 8.80% 8.60% 8.70% 8.05% 8.18%
6.31% 6.91% 6.63% 4.26% 3.86% 2.55% 3.13% 3.51% 3.68% 2.36% 1.47% 1.22%
29.77% 28.26% 28.19% 30.22% 29.61% 28.79% 28.65% 28.37% 28.39% 29.63% 31.17% 31.29%
No. of Shareholders 54,66256,32256,98659,65461,17556,58356,22156,27252,33650,65653,68355,280

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls